Refractory Reflux Esophagitis
1
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
EisaiE3810
Eisairabeprazole sodium
Clinical Trials (2)
Total enrollment: 2,494 patients across 2 trials
Double-blind Comparative Study of E3810 Tablets (10 or 20 mg b.i.d.) to Evaluate Efficacy and Safety in Patients With Refractory Reflux Esophagitis
Start: Oct 2008Est. completion: Mar 2010337 patients
Phase 2/3Completed
Quality of Life in New Treatable Therapy as Rabeprazole Option for Refractory Reflux Esophagitis
Start: Jan 2011Est. completion: Aug 20132,157 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 companies competing in this space